Search
Displaying 511–520 of 651 for “retinal diseases”
-
Turning Stem Cells Into "Super" Models
Research NewsScientists have found a way to take a small skin or blood sample from a patient, turn back the clock on those sample cells so they become stem cells, and then coax them forward to become photoreceptors, or any other cell type in the body.
-
The Foundation's 5 Most Asked Questions About Clinical Trials
Research NewsWhat you need to know (and what to expect) about clinical trials.
-
Research News
The study is designed to evaluate the pharmacodynamics, safety and tolerability of emixustat in subjects with macular atrophy secondary to Stargardt disease.
-
Films & Documentaries Showcase
Celebrating the powerful stories of individuals in the blind and low vision community through the art of film.
-
Leber Congenital Amaurosis Research Advances
Research NewsRecent developments in research on Leber congenital amaurosis.
-
About Page
The Foundation Fighting Blindness Brand Ambassador Program empowers passionate individuals affected by blinding diseases to share their stories, raise awareness, and inspire action in the fight against vision loss. Together, we’re amplifying voices and accelerating our path to treatments and cures.
-
Ocugen Launches Phase 2/3 Clinical Trial for Stargardt Disease Gene-Modifier Therapy
Research NewsThe therapy delivers copies of the RORA gene to address multiple disease pathways.
-
Want to support this historic event? Sponsorship and exhibitor opportunities are available for organizations, foundations, and industry partners dedicated to advancing retinal research and innovation. Learn more by sending an email to Partnerships@FightingBlindness.org.
-
Eye on the Cure Podcast | Episode 86: Lenore von Krusenstiern, MD, PhD
Eye on the CureDr. Lenore von Krusenstiern talks about Bluerock’s clinical trial for a photoreceptor replacement therapy for people with inherited retinal conditions such as retinitis pigmentosa and cone-rod dystrophy.
-
Research News
The company is planning a Phase 2/3 clinical trial for the therapy in late 2025.
.png)
